Conatus Pharmaceuticals (CNAT) Misses Q1 EPS by 1c

Conatus Pharmaceuticals (NASDAQ: CNAT) reported Q1 EPS of ($0.36), $0.01 worse than the analyst estimate of ($0.35).

Cash, cash equivalents and marketable securities were $32.6 million at March 31, 2016, compared with $36.5 million at December 31, 2015. The company believes current financial resources are sufficient to maintain operations and ongoing clinical development activities for at least the next 12 months.

For earnings history and earnings-related data on Conatus Pharmaceuticals (CNAT) click here.

You May Also Be Interested In

• TJX stock drops as profit outlook falls short of analyst estimates
• Target (TGT) Tops Q2 EPS by $1.78, Beats on Revenue; Offers FY27 EPS Guidance
• Opera Limited (OPRA) Misses Q2 EPS by 1c ; Offers Guidance